TY - JOUR
T1 - Syndecan 1 (CD138) serum levels
T2 - A novel biomarker in predicting liver fibrosis stage in patients with hepatitis C
AU - Zvibel, Isabel
AU - Halfon, Phillipe
AU - Fishman, Sigal
AU - Penaranda, Guillaume
AU - Leshno, Moshe
AU - Or, Anat Bet
AU - Halpern, Zamir
AU - Oren, Ran
PY - 2009
Y1 - 2009
N2 - Background and Aims: Syndecan 1 (CD 138) is a cell surface proteoglycan shed by cells in several pathological conditions, including wound healing. The aim of this study was to test whether CD138 could serve as a non-invasive marker for detection of liver fibrosis and thereby reduce the need for liver biopsy. Patients and Methods: An estimation set of 134 patients and a validation set of 67 patients with chronic hepatitis C were studied. There were 80 normal healthy volunteers. Patients were staged according to liver biopsies (Metavir fibrosis staging, stage F0, n = 35; F1, n = 40; F2, n = 37, F3, n = 39; F4, n = 51). Serum CD138 levels were retrospectively measured by enzyme-linked immunoabsorbent assay the same day of the liver biopsy. The primary endpoints were the diagnostic values of CD138 for F2-F4, F3-F4 and F4. Results: Respective areas under receiver operating characteristic curve of CD138 for F2-F4, F3-F4 and F4 diagnosis were 0.82, 0.76 and 0.81. CD138 had a positive predictive value of 82% for F2-F4 diagnosis and a high negative predictive value (86%) and specificity (84%) for exclusion of F4. Conclusion: CD138 is a new simple non-invasive marker for predicting liver fibrosis in patients with chronic hepatitis C. The relevance of this marker in combination with other fibrosis markers should be explored.
AB - Background and Aims: Syndecan 1 (CD 138) is a cell surface proteoglycan shed by cells in several pathological conditions, including wound healing. The aim of this study was to test whether CD138 could serve as a non-invasive marker for detection of liver fibrosis and thereby reduce the need for liver biopsy. Patients and Methods: An estimation set of 134 patients and a validation set of 67 patients with chronic hepatitis C were studied. There were 80 normal healthy volunteers. Patients were staged according to liver biopsies (Metavir fibrosis staging, stage F0, n = 35; F1, n = 40; F2, n = 37, F3, n = 39; F4, n = 51). Serum CD138 levels were retrospectively measured by enzyme-linked immunoabsorbent assay the same day of the liver biopsy. The primary endpoints were the diagnostic values of CD138 for F2-F4, F3-F4 and F4. Results: Respective areas under receiver operating characteristic curve of CD138 for F2-F4, F3-F4 and F4 diagnosis were 0.82, 0.76 and 0.81. CD138 had a positive predictive value of 82% for F2-F4 diagnosis and a high negative predictive value (86%) and specificity (84%) for exclusion of F4. Conclusion: CD138 is a new simple non-invasive marker for predicting liver fibrosis in patients with chronic hepatitis C. The relevance of this marker in combination with other fibrosis markers should be explored.
KW - Hepatitis C
KW - Liverf ibrosis
KW - Syndecan 1
UR - http://www.scopus.com/inward/record.url?scp=58149484042&partnerID=8YFLogxK
U2 - 10.1111/j.1478-3231.2008.01830.x
DO - 10.1111/j.1478-3231.2008.01830.x
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 18694404
AN - SCOPUS:58149484042
SN - 1478-3223
VL - 29
SP - 208
EP - 212
JO - Liver International
JF - Liver International
IS - 2
ER -
